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Objectives. The present study was undertaken to prospectively
and comparatively evaluate the role of serial myocardial per-
fusion imaging and coronary angiography for the detection of
early vasculopathy in a large patient population and also to
determine the short- and long-term efficacy of augmented
immunosuppressive therapy in the potential reversal of the
early vasculopathy.
Background. Allograft vasculopathy is the commonest cause of
death after the first year of heart transplantation. Anecdotal
studies have reported the efficacy of augmented immunosuppres-
sive therapy after early detection of vascular involvement. How-
ever, no prospective study has evaluated the feasibility of early
detection and treatment of allograft vasculopathy.
Methods. In 76 cardiac allograft recipients, 230 coronary
angiographic and 376 scintigraphic studies were performed in a
follow-up period of 8 years. Angiography was performed at 1
month and every year after transplantation, and thallium-201
scintigraphy at 1, 3, 6 and 12 months after transplantation and
twice a year thereafter. Prospective follow-up of 76 patients
showed that 18 developed either angiographic or scintigraphic
evidence of coronary vasculopathy. All episodes were treated with
3-day methylprednisolone pulse and antithymocyte globulin.
Results. Twenty-two episodes of vasculopathy were diagnosed
and treated in these 18 patients. Of these 22 episodes, two were
detected only by angiography, seven by both angiography and
scintigraphy, four by scintigraphy and histologic evidence of
vasculitis and nine episodes only by thallium-201 scintigraphy
studies. Angiographic and/or scintigraphic resolution was ob-
served in 15 of the 22 episodes (68%) with augmented immuno-
suppression. The likelihood of regression was higher when treat-
ment was instituted within the first year of transplantation (92%)
than after the first year (40%) (p 5 0.033). Eighty percent of
patients who responded to follow-up.
Conclusions. The present study suggests that early detection of
allograft coronary vasculopathy is feasible with surveillance myo-
cardial perfusion or coronary angiographic studies. When identi-
fied early after transplantation, immunosuppressive treatment
may result in regression of coronary disease.
(J Am Coll Cardiol 1998;32:413–9)
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Transplant-associated vasculopathy is the most important lim-
iting factor in the long-term survival of cardiac allografts (1–5).
The incidence of angiographically demonstrable coronary ar-
tery disease has been reported in up to 15% of heart transplant
recipients at 1 year, 25% at 2 years and 50% at 5 years. Most
patients do not complain of chest pain on development of
coronary vasculopathy, and the clinical manifestations pre-
dominantly include ventricular arrhythmias, silent myocardial
infarction, congestive heart failure and sudden death (6,7).
Although the pathogenesis of the allograft vasculopathy has
not been clearly elucidated (8), the diffuse pattern of distribu-
tion, involvement of both arteries and veins and absence of
vasculopathy in vessels outside the graft suggest its relation to
rejection (9). The transplant-associated vasculopathy is char-
acterized by diffuse and concentric fibrointimal proliferation of
coronary vasculature including small intramyocardial branches
(10,11). The chronic fibrotic vascular changes have been
reported to evolve over months to years and may have their
origin in damage occurring during earlier reversible episodes
of rejection (12,13). The acute or subacute episodes of inflam-
matory changes in the vessel wall have been characterized by
the presence of mononuclear cell infiltrates as well as the
accumulations of immunoglobulin and complement and have
often been referred to as vascular rejection. If rejection is the
basis of vasculopathy, intervention with immunosuppressive
therapy should be able to prevent progression of the disease
process (14). We have previously reported 4 patients who
developed evidence of diffuse coronary involvement on coro-
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nary angiography within 2 months after heart transplantation
(15). All patients were treated with methylprednisolone and
antithymocyte globulin, and all demonstrated complete angio-
graphic resolution of vascular occlusion.
This prospective study was undertaken in a large patient
cohort with the following objectives: i) to evaluate and com-
pare the role of serial myocardial perfusion imaging and
coronary angiography in early recognition of coronary vascu-
lopathy; ii) to determine the short-term effects of augmenta-
tion of immunosuppressive therapy on early allograft vascu-
lopathy; and iii) to assess the long-term efficacy of early
intervention.
Methods
Study protocol. A total of 76 patients who received ortho-
topic heart transplantation at the Sant Pau Hospital, Barcelona
were prospectively screened for the development of graft
vasculopathy from the first month after transplantation. The
evaluation included 230 coronary angiography procedures and
376 myocardial perfusion imaging studies over a period of 8
years (March 1986 to February 1994). Coronary angiography
was performed at the end of the first month and yearly
thereafter. The exercise thallium-201 studies were performed
at 1, 3, 6 and 12 months during the first year and biannually
thereafter.
Of the 76 patients, 51 have not shown any angiographic or
scintigraphic evidence of coronary vasculopathy. Of the re-
maining 25 patients, 6 developed focal eccentric coronary
disease (Stanford, type A classification); 1 patient suffered
sudden cardiac death and demonstrated vascular obstruction
at necropsy. In the remaining 18 patients (15 men and 3
women; age range, 8 to 58 years; mean age, 42 6 14 years),
coronary artery disease was detected by one or more diagnostic
techniques on 22 occasions (Table 1). Included in the present
study are all 18 patients who developed vascular involvement
during follow-up and were treated with augmented immuno-
suppression. Patients with angiographic evidence of focal
coronary disease were excluded from the study.
Thallium-201 scintigraphy and myocardial perfusion ab-
normalities. Symptom-limited (fatigue and dyspnea) exercise
test was performed based on Bruce protocol with continuous
electrocardiographic monitoring. At peak exercise thallium-
201 (111 MBq or 3 mCi) was injected, and exercise was
continued for an additional minute. Single-photon emission
computed tomography studies were acquired using a rotating
gamma camera (Elscint Helix HR) equipped with a low
energy, high resolution collimator; 15% windows were cen-
tered over both 70 and 167 keV photopeaks. Sixty projections
of 20 s each were acquired in step-and-shoot mode over a 180°
circular orbit, from the 45° right anterior oblique to the 45° left
posterior oblique view, with a 1.43 zoom factor and 64 3 64
word matrix. Each projection image was corrected for intrinsic
nonuniformity with a 120 million count image. Series of
6.2-mm thick transverse slices were reconstructed using filtered
backprojection with a Ramp filter, and smoothed with a
Butterworth filter (cutoff frequency 0.35 cycle per pixel, power
5). A reconstructed transaxial image containing a good-sized
cavity was selected, and the long axis in that transaxial plane
was manually drawn and overlaid on the image. The image
volume was then reformatted along planes perpendicular to
the transaxial plane and parallel to the long axis. A sagittal slice
was selected, and the long axis projection was drawn. The
short-axis images were extracted as the planes perpendicular to
the other two axes. No attenuation or scatter correction was
applied. The reconstructed tomographic data were displayed in
the three planes encompassing the entire left ventricle, nor-
malizing the slice set to the maximum of activity. Polar maps
were subsequently generated for display.
Coronary angiography and identification of allograft vas-
culopathy. All patients underwent catheterization after the
first month and first year of transplantation and then yearly.
The catheterization was repeated in the interim if the thallium-
201 scintigraphy demonstrated perfusion abnormalities. After
administration of local anesthesia, a 6-F sheath was inserted in
the right femoral artery. Selective angiograms for the left and
right coronary arteries in standard orthogonal views were
obtained using the Judkins technique. Identical views in serial
studies were performed in an individual. Angiograms were
interpreted independently by two experienced angiographers.
A coronary artery or its branches were considered diseased
when at least minor luminal irregularities were seen in more
than two orthogonal views. Patients with eccentric and local-
ized abnormality consistent with Stanford type I lesion were
excluded (16).
Endomyocardial biopsy, criteria for cellular rejection and
vasculitis. During the first year after heart transplantation
sequential endomyocardial biopsies were performed in every
patient for surveillance of cellular allograft rejection. Biopsy
interpretation was made according to the Working Formula-
tion of the International Society of Heart and Lung Transplan-
tation (ISHLT) (17). Acute rejection was treated when evi-
dence of myocardial cell damage was detected in the biopsy
Abbreviation and Acronym
ISHLT 5 International Society of Heart and Lung Transplantation
Table 1. Diagnosis of Early Allograft Vasculopathy
Diagnostic Criteria
Number of
Episodes
I. Abnormal thallium-201 perfusion scan and abnormal
coronary angiogram
7
II. Abnormal thallium-201 perfusion scan and vasculitis in EMB
(normal coronary angiogram)
4
III. Abnormal thallium-201 perfusion scan only (normal coronary
angiogram)
9
IV. Abnormal coronary angiogram only (normal thallium-201
perfusion scan)
2
Total 22
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specimens (ISHLT grade 2 or more). In the event of cellular
rejection, a repeat endomyocardial biopsy was performed 5 to
7 days after the treatment for rejection.
A special effort was made to identify arterioles for the
diagnosis of vasculitis. Arterioles with clearly definable internal
and external elastic laminae were evaluated for the presence of
endothelial swelling, intimal monocellular infiltration, intimal
proliferation or fibrinoid necrosis of the medial muscular layer
(Fig. 2). No immunohistochemical studies were performed for
detection of vascular deposition of immunoglobulins or com-
plement.
Immunosuppressive therapy and management of allograft
rejection. Immediately after transplantation antithymocyte
globulin was administered to all patients for 7 to 10 days.
Corticosteroids were given in the form of methylprednisolone
bolus of 1 g, 500 mg and 500 mg for the first 3 days following
transplantation. Subsequently, patients have been managed
with triple immunosuppressive treatment of oral cyclosporine,
azathioprine and prednisone. Cyclosporine doses were ad-
justed to whole blood levels of 400–800 ng/ml using polyclonal
and 100–200 ng/ml with monoclonal antibody kits. Azathio-
prine was started as a 1–2 mg/kg dose and was adjusted to the
total white blood cell count. Prednisone was maintained at
0.1–0.2 mg/kg/day.
Treatment of acute cellular rejection comprised a 3-day
course of intravenous methylprednisolone (1,000–500–500 mg
or 500–250–250 mg, respectively) and antithymocyte globulin
(5 mg/kg/day with adjustment to T-cell level between 100 and
200 mm3). Two patients required OKT3 therapy for refractory
rejection.
Augmented immunosuppressive treatment for vasculopa-
thy. The episodes of early vasculopathy were treated with
augmented immunosuppressive therapy with methylpred-
nisolone and antithymocyte serum for 3 days identical to the
treatment of acute cellular rejection. After 7 to 10 days of
treatment for the vascular obstruction, coronary angiography
and thallium-201 scintigraphy were repeated for comparison
with the pretreatment investigations.
Statistical analysis. The differences between the propor-
tion of episodes of vascular occlusion resolved by augmented
immunosuppression before the first year and after that period
was assessed by a chi-square test. The freedom from episodes
of vascular occlusion was determined by the Kaplan–Meier
method.
Results
Myocardial perfusion abnormalities in early graft vascu-
lopathy. In the 8-year interval, 22 episodes of early vasculopa-
thy were diagnosed in 18 patients and treated with augmented
immunosuppression. One patient suffered three episodes, and
2 other patients demonstrated two episodes of vasculopathy
each. The cumulative percentage of being free of vasculopathy
at 1, 3 and 5 years was 87%, 82% and 68%, respectively.
Scintigraphic evidence of perfusion abnormality was ob-
served in 20 episodes (Table 1). Of these, seven were accom-
panied by angiographic coronary disease (Fig. 1) and four by
pathologic evidence of vasculitis (Fig. 2); nine of the 20
episodes were solely detected by thallium-201 perfusion scan.
The remaining two of the 22 episodes not evident on perfusion
scintigraphy were detected by coronary angiography.
The scintigraphic appearance of the vasculopathy was usu-
ally confined to one coronary territory (Table 2). The anterior,
anteroseptal or apical involvement was observed on 11 occa-
sions, and inferior or posterior involvement was observed in
the remaining nine. In the patient with three episodes of
vasculopathy (patient #3), the first involved the anterior
myocardial region, the second the anteroseptal region and the
third episode detected at coronary angiography was not dis-
cernible on thallium-201 imaging. In the other 2 patients with
two episodes of vasculopathy each (patients #8 and #15), the
primary and recurrent episodes involved the same coronary
territory as identified by thallium scintigraphy.
Effect of augmented immunosuppression on early graft
vasculopathy. Of 22 episodes of early graft vasculopathy
treated with increased immunosuppression, 15 demonstrated
resolution of the myocardial perfusion and/or angiographic
abnormalities (68%) (Table 2, Fig. 1). Of the seven remaining
unresolved episodes, two were recurrent episodes. The epi-
sodes treated within the first year after transplantation had a
higher probability of resolution (11 out of 12, 92%) compared
with those treated thereafter (4 out of 10, 40%) (p 5 0.033)
Figure 1. Angiographic evidence of early
graft vasculopathy that responded to in-
creased immunosuppressive therapy.
Coronary angiography in left anterior
oblique view in patient #1 demonstrated
diffuse coronary artery disease 2 months
after transplantation (A). The angio-
graphic evidence of vasculopathy was also
accompanied by anterior myocardial per-
fusion defect. The angiographic abnor-
mality showed resolution with augmented
immunosuppression. There was a com-
plete resolution of scintigraphic perfusion
abnormality. The patient continues to
show angiographically normal coronary
arteries 126 months after operation.
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(Table 3). The resolution of early graft vasculopathy was
observed in all four episodes that were associated with patho-
logic evidence of vasculitis and seven of nine episodes (78%)
detected by myocardial perfusion scan alone. When the evi-
dence of vasculopathy was detected by angiography, only four
of the nine episodes showed resolution with treatment.
Long-term effects of resolution of early graft vasculopathy.
Of the 18 patients with 22 episodes, 10 patients demonstrated
resolution of their early graft vasculopathy, and 5 patients did
not show any benefit. The remaining 3 patients sustained
recurrent episodes of vasculopathy. These 18 patients were
followed for 61 6 32 months (median, 64 months).
Of the 10 patients who had demonstrated resolution and
did not develop recurrent vasculopathy, 6 showed normal
coronary angiograms and normal perfusion scans up to 124
months of follow-up (patients #1, 2, 7, 11, 12 and 17), and 2
died of acute cardiac rejection (patient #9) and cerebrovascu-
lar accident (patient #10) at 64 and 35 months with normal
coronary arteries. The remaining 2 of the 10 patients have
demonstrated an eventful course; 1 has developed diffuse
coronary disease 32 months after treatment of vasculopathy
(patient #13), and another patient presented with acute
myocardial infarction and congestive heart failure 32 months
after treatment and underwent retransplantation (patient
#14).
Five of the 18 patients had failed to respond to augmented
immunosuppressive therapy. While 1 of them showed late
resolution (patient #16), the remaining 4 patients died with
diffuse coronary artery disease and congestive heart failure and
acute myocardial infarction within 11 to 33 months of treat-
ment (patients #4, 5, 6 and 18).
The remaining 3 of the 18 patients developed recurrent
vasculopathy. The first of the 3 patients showed recurrences of
vasculopathy at 27 and 44 months (patient #3), developed
congestive heart failure 1 year after the last episode and was
retransplanted. The second patient showed two episodes of
vasculopathy; both resolved with increased immunosuppres-
sion, but the patient has developed diffuse coronary artery
disease at 10 years of follow-up (patient #8). The third patient
showed complete resolution of his primary episode but devel-
oped a recurrence 22 months later (patient #15). The recur-
rent episode did not respond to immunosuppression. However,
the subsequent set of studies performed in this patient re-
vealed normal arteries; he is free of epicardial coronary disease
at 72 months of follow-up. Eight of the 13 initial responders
(62%) and only 1 of the 5 nonresponders (20%) were free of
coronary occlusion at the end of follow-up.
Discussion
The present study indicates that detection of early allograft
vasculopathy is feasible by serial myocardial perfusion scans.
Twenty episodes of vasculopathy were detected by thallium-
201 scintigraphy in a prospective follow-up of 76 patients. Of
the 20 episodes, 13 were not apparent on coronary angiograms,
suggesting that perfusion abnormalities may precede angio-
graphic evidence of the disease. These results differ from
previous reports of myocardial perfusion scans that failed to
confirm the clinical utility of the procedure (18–23). The
perfusion scans in the referred studies were performed late
after transplantation, after diffuse and chronic involvement of
the coronary arteries had probably occurred; at this time,
Figure 2. Histologic evidence of vascu-
litis. Endomyocardial biopsy specimen 1
month after heart transplantation in pa-
tient #10. A myocardial arteriole dem-
onstrates evidence of vasculitis with in-
timal proliferation and edema almost
obliterating the lumen (hematoxylin and
eosin, 3200). In addition to vasculitis,
there was an evidence of ISHLT grade
3A parenchymal rejection (B). This pa-
tient demonstrated anterior myocardial
perfusion abnormality in thallium perfu-
sion scan. He was treated with increased
immunosuppressive therapy with com-
plete resolution of perfusion defect. This
patient demonstrated normal coronary
arteries at 34 months, when he died of a
cerebrovascular accident.
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regional perfusion defects are not likely to be detected due to
balanced ischemia in various coronary territories (18,23). In
fact, 2 of the 76 patients in our cohort also did not demonstrate
perfusion abnormalities despite angiographic evidence of the
disease. These 2 patients with false negative scans had severe
diffuse triple vessel disease; 1 died and the other needed
retransplantation.
The process of early vasculopathy may be reversible by
augmentation of immunosuppressive therapy. In the present
study, two thirds of the episodes of vascular occlusion were
successfully treated. Vasculopathy treated within the first year
of transplantation demonstrated a 90% probability of resolu-
tion, whereas the results dropped to 40% when the vascular
process was detected after 1 year. The reason for this finding
could be that early vasculopathy is likely to be associated with
inflammatory process (24), and therefore more susceptible to
immunosuppression, whereas after the first year, the likelihood
of benefit is reduced due to the development of chronic
obliterative changes of intimal proliferation and fibrosis. This
would also explain the higher success rate seen in patients with
either histologic (100%) or scintigraphic evidence (78%) of
vascular involvement compared to those who had angiographic
evidence (45%) of vasculopathy. It is likely that angiographi-
cally discernible disease represents a later phase of the vascu-
lopathic change less amenable to medical treatment.
Treatment of vasculopathy detected early after transplan-
Table 2. Clinical, Angiographic and Scintigraphic Features of 22 Episodes of Vascular Occlusions Detected in 18 Patients and the Response
to Augmentation of Immunosuppressive Treatment
Patient
Age
(years)
and
gender
Posttransplant
interval
Tl-201
(pre)
Tl-201
(post)
Angiogram
(pre)
Angiogram
(post)
EMB*
ISHLT
$2 Response† Follow-up
Abnormal thallium-201 and abnormal coronary angiogram
1. 24M 2 mo Anterior Normalization Diffuse Normalization 1 126 mo normal coronaries
2. 58M 4 mo Apical Normalization Diffuse Normalization 1 48 mo normal coronaries
3-1.‡ 39F 12 mo Anterior Normalization Diffuse Normalization 1 39 mo new episode 1 CHF
3-2.‡ 42F 39 mo Anteroseptal Persistent Diffuse Persistent 58 mo new episode 1 CHF
4. 30M 42 mo Inferior Persistent Diffuse Persistent 24 mo diffuse coronary 1 CHF,
died 80 mo CAD
5. 50M 42 mo Septal Persistent Diffuse Persistent 51 mo diffuse coronary 1 CHF,
died 70 mo CAD
6. 51M 48 mo Anterior 1
apicolateral
Persistent Diffuse Persistent 15 mo coronary diffuse 1 CHF,
died 70 mo CAD
Abnormal thallium-201 and vasculitis at EMB
7. 53M 1 mo Posterior Normalization Normal Normal 1 1 36 mo normal coronaries
8-1.‡ 42F 1 mo Anterior Normalization Normal Normal 1 53 mo new episode
9. 8M 1 mo Posterior Normalization Normal Normal 1 1 64 mo died acute rejection,
normal coronaries
10. 57M 1 mo Anterior Normalization Normal Normal 1 1 35 mo died CVA, normal
coronaries
Abnormal thallium-201 and normal coronary angiogram
11. 56M 3 mo Inferior Normalization Normal Normal 1 1 64 mo normal coronaries
12. 52M 4 mo Anteroseptal Normalization Normal Normal 1 96 mo normal coronaries
13. 47M 4 mo Anterior 1
apicolateral
Normalization Normal Normal 1 1 36 mo diffuse coronary disease
14. 39M 7 mo Inferior Normalization Normal Normal 1 39 mo AMI 1 CHF, 70 mo
retransplantation
15-1.‡ 28M 23 mo Inferoapical Normalization Normal Normal 1 35 mo new episode
15-2.‡ 29M 35 mo Inferior Persistent Normal Normal 72 mo normal coronaries
16. 55M 30 mo Inferolateral Persistent Normal Normal 60 mo normal coronaries
8-2.‡ 48F 53 mo Anterior Normalization Normal Normal 1 120 mo diffuse coronary disease
17. 50M 54 mo Inferior Normalization Normal Normal 1 78 mo normal coronaries
Normal thallium-201 abnormal coronary angiogram
18. 27M 11 mo Normal Diffuse Persistent Diabetes, 22 mo died AMI
3-3.‡ 44F 58 mo Normal Diffuse Normalization 1 87 mo CHF 1
retransplantation
pre, investigation at the time of diagnosis of vascular occlusion before treatment; post, investigation after immunosuppressive treatment; CAD, coronary artery
disease; CVA, cardiovascular accident; AMI, acute myocardial infarction. *ISHLT rejection of grade $2. †Response to immunosuppressive treatment: (1), complete
resolution. ‡Patients #3, 8 and 15 have demonstrated more that one episode of diffuse vasculopathy. Vasculitis in EMB was observed only in patients #7–10.
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tation should prevent development of chronic occlusive vascu-
lar disease. In the present study, 80% of patients who were
successfully treated and did not develop recurrent disease
remained free of coronary disease up to 3 to 10 years of
follow-up. On the other hand, 80% of the patients who failed
therapy died of acute myocardial infarction or congestive heart
failure due to chronic diffuse coronary artery disease. Although
our results suggest long-term benefit of early treatment, a
controlled randomized study will be required to substantiate
these findings.
The strategies of the detection and treatment of early stages
of rejection-related vasculopathy need to be reconsidered. The
first coronary angiography is performed in most centers after
the first year of transplantation (25–27). This approach may
fail to detect potentially treatable episodes of early vasculopa-
thy. On the other hand, even if vascular involvement is
detected by coronary angiography, by myocardial perfusion
scintigraphy or by intravascular ultrasound, medical treatment
is not considered (18–23,25–30). The findings of the present
study suggest that more frequent scintigraphic or angiographic
studies should be performed during the first year of transplan-
tation in order to detect the early vasculopathic changes. If
detected, an aggressive immunosuppressive treatment—
similar to that employed in the setting of an acute cellular
rejection—should be considered. Although the likelihood of
reversibility is greater at the early stages of transplantation, our
findings indicate that treatment should probably be attempted
when the vasculopathy is detected after the first year of the
operation.
Limitations of the study. In patients included in group III
(abnormal perfusion studies with normal coronary artery anat-
omy) the possibility of false positive results should be consid-
ered. Due to the lack of an adequate gold standard, this issue
is difficult to address.
This is primarily an observational, uncontrolled study not
subjected to blinding or randomization. Therefore, the conclu-
sions reached herein must be considered with care and con-
trasted with future studies designed to confirm the reported
findings.
Conclusions. The present study demonstrates the feasibil-
ity of detection of early vasculopathy after heart transplanta-
tion by serial myocardial perfusion studies and early coronary
angiography. The augmented immunosuppressive therapy re-
sults in resolution of the vascular involvement especially if
detected in the first year after transplantation. The treatment
could result in long-term prevention of late vascular disease.
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